Cytodyn Inc (CYDY)

[docj]

Tiny-Ad-8280

🧬 A Tiny Dose of CYDY — Countdown to ESMO - A New Series - 🗓 49 Days Until May 15th
🚨 Title: Stage 4. Terminal. Now Cancer-Free?! At 25¢?!

Let’s set the stage…

Stage 4 metastatic triple-negative breast cancer (mTNBC) is a death sentence.
It spreads fast. It ignores most treatments.
Once it hits your brain, lungs, or liver… you’re done.

📉 Median survival? Around 12 months.
📈 Long-term survival? Almost nonexistent.
🎯 Cure? Not a thing.

So what if I told you a company trading for 25¢ just treated 30 of these terminal patients…
…and now says a subgroup is 36+ months out, alive and cancer-free?

You read that right.
No cancer. No progression. No recurrence.

🧪 The drug? Leronlimab.
👨‍⚕️ The company? CytoDyn ($CYDY).
📍 The event? ESMO Breast Cancer Conference — May 15th.

This isn’t hype. It’s from their February press release:

“A small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab… and currently identify as having no evidence of ongoing disease.”

That’s unheard of.
That’s not how stage 4 works.
That’s not supposed to happen — but it did.

And the world finds out what really happened 49 days from now.

👀 Until then…
Sit tight. Do your homework.

And check back tomorrow for your next Tiny Dose of CYDY.